Credit Suisse Group set a $143.00 target price on AnaptysBio (NASDAQ:ANAB) in a research report released on Friday, November 9th. The firm currently has a buy rating on the biotechnology company’s stock.
A number of other brokerages have also recently issued reports on ANAB. Cantor Fitzgerald reaffirmed a buy rating and set a $140.00 target price on shares of AnaptysBio in a research report on Tuesday, October 16th. Jefferies Financial Group reaffirmed a buy rating and set a $121.00 target price on shares of AnaptysBio in a research report on Tuesday, August 7th. Stifel Nicolaus set a $127.00 price objective on AnaptysBio and gave the company a buy rating in a research report on Friday, September 14th. Zacks Investment Research raised AnaptysBio from a hold rating to a buy rating and set a $93.00 price objective for the company in a research report on Monday, August 13th. Finally, Wedbush reissued an outperform rating and issued a $138.00 price objective on shares of AnaptysBio in a research report on Tuesday, September 18th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of Buy and an average target price of $129.09.
NASDAQ ANAB traded down $2.33 on Friday, hitting $72.25. 332,900 shares of the company were exchanged, compared to its average volume of 369,349. The company has a market cap of $2.00 billion, a PE ratio of -47.53 and a beta of 3.42. AnaptysBio has a twelve month low of $62.56 and a twelve month high of $134.00.
A number of institutional investors have recently added to or reduced their stakes in ANAB. Principal Financial Group Inc. raised its stake in AnaptysBio by 84.2% during the first quarter. Principal Financial Group Inc. now owns 6,112 shares of the biotechnology company’s stock worth $637,000 after acquiring an additional 2,793 shares in the last quarter. Guggenheim Capital LLC acquired a new position in AnaptysBio during the first quarter worth $2,601,000. Legal & General Group Plc increased its stake in shares of AnaptysBio by 53.3% in the first quarter. Legal & General Group Plc now owns 6,945 shares of the biotechnology company’s stock valued at $722,000 after buying an additional 2,414 shares in the last quarter. Royal Bank of Canada increased its stake in shares of AnaptysBio by 1,342.2% in the first quarter. Royal Bank of Canada now owns 39,877 shares of the biotechnology company’s stock valued at $4,150,000 after buying an additional 37,112 shares in the last quarter. Finally, Handelsbanken Fonder AB increased its stake in shares of AnaptysBio by 100.0% in the second quarter. Handelsbanken Fonder AB now owns 16,000 shares of the biotechnology company’s stock valued at $1,137,000 after buying an additional 8,000 shares in the last quarter.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Featured Story: What is a Tariff?
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.